Use of hyaluronic acid as an immunosuppressant
CA 2229282 C · Owner: Buelow, Roland · Inventors: Buelow, Roland; Lussow, Alexander R.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A pharmaceutical formulation of hyaluronic acid is administered to a patient suffering from undesirable T cell activity. The hyaluronic acid inhibits T cell activity at doses that are well-tolerated by the recipient. Conditions suitable for treatment include graft vs. host disease graft rejection and , certain autoimmune diseases having a T cell component.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 27, 1996 and granted January 29, 2002. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 27, 2016.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 27, 2018.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.